NZ500288A - Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system - Google Patents
Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating systemInfo
- Publication number
- NZ500288A NZ500288A NZ500288A NZ50028898A NZ500288A NZ 500288 A NZ500288 A NZ 500288A NZ 500288 A NZ500288 A NZ 500288A NZ 50028898 A NZ50028898 A NZ 50028898A NZ 500288 A NZ500288 A NZ 500288A
- Authority
- NZ
- New Zealand
- Prior art keywords
- carbon dioxide
- benzamide
- gastric
- pharmaceutical composition
- active principle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A gastric-retained pharmaceutical composition, characterised in that it comprises: (a) an active principle consisting of a benzamide such as tiapride or amisupride, or one of its salts; (b) a system for generating carbon dioxide, comprising a carbon dioxide generator agent such as calcium carbonate or sodium bicarbonate, and a monocarboxylic acid or a polycarboxylic acid ; and (c) means for partially retaining the carbon dioxide generated by the carbon dioxide generating means, such as a hydrophilic polymer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9704803A FR2762213B1 (en) | 1997-04-18 | 1997-04-18 | PHARMACEUTICAL COMPOSITION WITH GASTRIC RETENTION |
PCT/FR1998/000755 WO1998047506A1 (en) | 1997-04-18 | 1998-04-15 | Gastric-retained pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ500288A true NZ500288A (en) | 2001-03-30 |
Family
ID=9506077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ500288A NZ500288A (en) | 1997-04-18 | 1998-04-15 | Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0983065A1 (en) |
JP (1) | JP2001523241A (en) |
KR (1) | KR20010006353A (en) |
CN (1) | CN1252720A (en) |
AR (1) | AR015586A1 (en) |
AU (1) | AU737634B2 (en) |
CA (1) | CA2286081A1 (en) |
FR (1) | FR2762213B1 (en) |
HU (1) | HUP0002455A3 (en) |
IL (1) | IL131995A0 (en) |
JO (1) | JO2017B1 (en) |
MA (1) | MA26482A1 (en) |
NO (1) | NO995039L (en) |
NZ (1) | NZ500288A (en) |
PE (1) | PE68199A1 (en) |
PL (1) | PL336273A1 (en) |
TN (1) | TNSN98049A1 (en) |
WO (1) | WO1998047506A1 (en) |
ZA (1) | ZA983258B (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6169094B1 (en) * | 1998-07-14 | 2001-01-02 | Sanofi-Synthelabo | Compositions of (S) (-)-amisulpride |
FR2784583B1 (en) | 1998-10-16 | 2002-01-25 | Synthelabo | PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE |
FR2790388B1 (en) * | 1999-03-04 | 2001-04-13 | Synthelabo | PHARMACEUTICAL COMPOSITIONS COMPRISING A BENZAMIDE AND AT LEAST ONE ABSORPTION PROMOTER |
EP1245227A1 (en) | 2001-03-31 | 2002-10-02 | Jagotec Ag | A pharmaceutical tablet system that floats in the stomach for programmed release of active substance and process of producing buoyant material contained in same |
WO2009157711A2 (en) * | 2008-06-24 | 2009-12-30 | Park Eun-Seok | Gastro-retentive porous tablet and method for preparing same |
FR2949061B1 (en) * | 2009-08-12 | 2013-04-19 | Debregeas Et Associes Pharma | FLOATING MICROGRANULES |
EP2719376B1 (en) | 2012-10-12 | 2015-03-04 | Omya International AG | Gastroretentive drug formulation and delivery systems and their method of preparation using functionalized calcium carbonate |
KR20200110317A (en) | 2017-12-05 | 2020-09-23 | 선오비온 파마슈티컬스 인코포레이티드 | Crystal form and method for preparing the same |
KR20200110648A (en) | 2017-12-05 | 2020-09-24 | 선오비온 파마슈티컬스 인코포레이티드 | Non-racemic mixtures and uses thereof |
JP7044649B2 (en) * | 2018-06-28 | 2022-03-30 | 株式会社ファンケル | Intragastric floating tablets |
AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
WO2023214018A1 (en) | 2022-05-06 | 2023-11-09 | Galenix Innovations | Gastro-retentive swellable sustained release composition |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2415099A1 (en) * | 1978-01-20 | 1979-08-17 | Ile De France | NEW DERIVATIVES OF 4-AMINO-5-ALKYLSULFONYL ORTHO-ANISAMIDES, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS PSYCHOTROPES |
FR2554718B1 (en) * | 1983-11-14 | 1986-04-04 | Ethypharm Sa | NEW ORAL SULPIRIDE FORMS FOR SULPIRIDE |
FR2556964A1 (en) * | 1983-12-23 | 1985-06-28 | Ile De France | NEW GALENIC FORMS OF SULPIRIDE USED ORALALLY |
JPS62178518A (en) * | 1986-01-30 | 1987-08-05 | Toho Yakuhin Kogyo Kk | Novel long-acting sulpiride tablet |
JPH0776172B2 (en) * | 1986-04-16 | 1995-08-16 | 藤沢薬品工業株式会社 | Matrice locks |
CA2039742A1 (en) * | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
-
1997
- 1997-04-18 FR FR9704803A patent/FR2762213B1/en not_active Expired - Fee Related
-
1998
- 1998-04-15 CA CA002286081A patent/CA2286081A1/en not_active Abandoned
- 1998-04-15 WO PCT/FR1998/000755 patent/WO1998047506A1/en not_active Application Discontinuation
- 1998-04-15 JP JP54514398A patent/JP2001523241A/en active Pending
- 1998-04-15 IL IL13199598A patent/IL131995A0/en unknown
- 1998-04-15 PL PL98336273A patent/PL336273A1/en unknown
- 1998-04-15 KR KR1019997009438A patent/KR20010006353A/en not_active Application Discontinuation
- 1998-04-15 HU HU0002455A patent/HUP0002455A3/en unknown
- 1998-04-15 CN CN98804269A patent/CN1252720A/en active Pending
- 1998-04-15 AU AU73416/98A patent/AU737634B2/en not_active Ceased
- 1998-04-15 EP EP98920623A patent/EP0983065A1/en not_active Ceased
- 1998-04-15 NZ NZ500288A patent/NZ500288A/en unknown
- 1998-04-16 TN TNTNSN98049A patent/TNSN98049A1/en unknown
- 1998-04-17 ZA ZA983258A patent/ZA983258B/en unknown
- 1998-04-17 AR ARP980101773A patent/AR015586A1/en unknown
- 1998-04-17 PE PE1998000281A patent/PE68199A1/en not_active Application Discontinuation
- 1998-04-17 MA MA25037A patent/MA26482A1/en unknown
- 1998-04-18 JO JO19982017A patent/JO2017B1/en active
-
1999
- 1999-10-15 NO NO995039A patent/NO995039L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0983065A1 (en) | 2000-03-08 |
AU737634B2 (en) | 2001-08-23 |
WO1998047506A1 (en) | 1998-10-29 |
FR2762213B1 (en) | 1999-05-14 |
JP2001523241A (en) | 2001-11-20 |
ZA983258B (en) | 1998-10-19 |
KR20010006353A (en) | 2001-01-26 |
HUP0002455A2 (en) | 2000-12-28 |
JO2017B1 (en) | 1999-05-15 |
NO995039D0 (en) | 1999-10-15 |
TNSN98049A1 (en) | 2005-03-15 |
AR015586A1 (en) | 2001-05-16 |
AU7341698A (en) | 1998-11-13 |
MA26482A1 (en) | 2004-12-20 |
CN1252720A (en) | 2000-05-10 |
PL336273A1 (en) | 2000-06-19 |
IL131995A0 (en) | 2001-03-19 |
FR2762213A1 (en) | 1998-10-23 |
HUP0002455A3 (en) | 2001-01-29 |
NO995039L (en) | 1999-12-17 |
PE68199A1 (en) | 1999-07-15 |
CA2286081A1 (en) | 1998-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ500288A (en) | Gastric-retained pharmaceutical composition comprising benzamide as the active principle and a carbon dioxide generating system | |
SE8902288L (en) | PHARMACEUTICAL COMPOSITION | |
IL114449A0 (en) | Multiple unit tableted dosage form | |
UA66847C2 (en) | Solid rapidly decomposing fizzy dosage form of selegiline and method for its production | |
BR9815064A (en) | Detergent tablet | |
EP0221732A3 (en) | Sustained release tablets | |
ZA947337B (en) | Use of angiotensin II analogs in tissue repair | |
DK0730465T3 (en) | Use of angiotensin III and analogues thereof for tissue repair | |
MXPA97002401A (en) | Antiinflammatory agent for external use. | |
BR9814217A (en) | Super absorbent gels based on poly (vinylguanidine) | |
FI974618A0 (en) | Divalent and trivalent small molecule selectin inhibitors | |
MX9702456A (en) | Liquid antacid compositions containing calcium carbonate and possibly simethicone as active compounds and monobasic potassium phosphate and potassium bicarbonate as buffer. | |
GR3019514T3 (en) | Pharmaceutical preparation for the treatment of prolonged coagulation time | |
DE69716586D1 (en) | BUFFERED ORTHOESTER POLYMERS CONTAINING MEDICINAL PRODUCTS | |
ATE307497T1 (en) | PHARMACEUTICAL COMPOSITION | |
PL346764A1 (en) | New oral formulation for 5-ht4 | |
ES2174293T3 (en) | PHARMACEUTICAL MICROSPHERES OF VALPROIC ACID FOR ORAL ADMINISTRATION. | |
HUP9903804A1 (en) | Antimycotic gel with high active substance release | |
DK0497724T3 (en) | Means for the disintegration of gallstones | |
AU2794289A (en) | Paging terminal apparatus with message storage and retransmission capability and method therefor | |
AU2651288A (en) | All-in-one boiler water treatment composition | |
AU4950296A (en) | Use of a pyruvate dehydrogenase activator for the treatment of ischaemia in limbs | |
GR77250B (en) | ||
FR2764281B1 (en) | PROCESS FOR THE PREPARATION OF COMPOSITIONS ESSENTIALLY COMPRISING AN ABSORBENT ANHYDROUS ALKALINE METAL CARBONATE | |
AR034993A1 (en) | MEDICINAL PRODUCT FOR THE PREVENTION OF CLINICAL AND SUBCLINICAL ACIDOSIS IN POLICAVITARY AND / OR RUMINANT ANIMALS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |